OptiBiotix Health PLC Extension of LPLDL® into Dairy Products (6863C)
12 February 2020 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 6863C
OptiBiotix Health PLC
12 February 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Extension of LP(LDL) (R) into Dairy Products
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its wholly-owned subsidiary ProBiotix
Health Ltd. ("ProBiotix"), has signed a licencing agreement with
Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's
patented probiotic strain LP(LDL) (R) into a functional yogurt
product in Uruguay, South America.
Under the terms of the agreement, SACCO S.r.l., which helped
develop the yogurt formulation, will supply ProBiotix's cholesterol
and blood pressure-reducing probiotic strain Lactobacillus
plantarum LP(LDL) (R), under a non-exclusive licence to Granja
Pocha for inclusion into fermented milk products, such as yogurts,
in Uruguay, with the aim of maximising the financial return for
both Granja Pocha and ProBiotix. There are no minimum sales targets
in the licencing agreement.
Granja Pocha, was founded in 1980 in the main dairy basin of the
Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since
2013, they have sold products under the Colonial brand, including
dulce de leche, cheeses, and yogurts. Granja Pocha describe
themselves as having become one of Uruguay's largest and most
respected dairy producers over the years.
Steve Prescott, CEO of ProBiotix, commented: "We are pleased to
announce this agreement with Granja Pocha, which will expand
LP(LDL) (R)'s presence into South America and extends its use into
dairy products. Granja Pocha was chosen as our partner to create a
functional yogurt containing LP(LDL) (R) because of their technical
expertise in dairy, track record of successfully launching new
products, and extensive knowledge of the local market. The work
carried out by Granja Pocha is a significant milestone as it
extends the use of LP(LDL) (R) into functional foods, in this case
dairy, which may be replicated in other territories. Functional
foods like this yogurt containing ProBiotix's LP(LDL) (R) provide a
unique format for customer to receive the cholesterol reducing
benefits of LP(LDL) (R) and capitalises on a growing industry trend
towards functional foods."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking) Tel: 020 7220 0500
goetzpartners securities Limited
Ulrich Kinzel Tel: 020 3859 7725
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBRGDDXSBDGGB
(END) Dow Jones Newswires
February 12, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024